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Summary
Background: In patients with acutely decompensated heart failure (ADHF), elevated serum con-
centration of cardiac troponin is an independent predictor of adverse cardiac events. In ADHF
with a preserved systolic blood pressure, treatment with intravenous vasodilator is recom-
mended. However, the effect of vasodilators on troponin concentrations has not been elucidated
well.
Methods and results: Serial high sensitive cardiac troponin I (hs-TnI) was measured in 36 patients
presenting with ADHF and preserved systolic blood pressure, of whom 20 were treated with
atrial natriuretic peptide (ANP) and 16 with nitrates. The concentrations of hs-TnI ranged from
0.069± 0.114 ng/ml at baseline to 0.076± 0.121 ng/ml at 5 h, 0.062± 0.106 ng/ml at 1 day, and
0.056± 0.089 ng/ml at day 7 (n = 36, ns). The relative change in hs-TnI between baseline and at
5 h, day 1 and day 7 were 1.13± 0.43, 0.95± 0.44 and 0.93± 0.64 in patients treated with ANP,
and 1.02± 0.19, 0.95± 0.31 and 1.19± 1.38 in patients treated with nitrates (ns; ANP versus
nitrates). On day 7, a hs-TnI change, >20% decrease from baseline, was observed in 55% patients
with ANP versus 56% patients with nitrates (ns). The cardiac event rates were similar in both
groups.
∗ Corresponding author. Tel.: +81 06 6482 1521; fax: +81 06 6482 7430.
E-mail address: cardioys@kuhp.kyoto-u.ac.jp (Y. Sato).
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Conclusions: In ADHF patients with preserved systolic blood pressure, the administration of intra-
venous vasodilators did not decrease hs-TnI over the ﬁrst 7 days. Treatments with ANP and nitrates
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population and of each study group are shown in Table 1.
The mean heart rate at baseline was signiﬁcantly higher in
patients treated with carperitide than those treated withwere associated with similar s
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Introduction
In the past two decades, the pharmacologic management of
chronic congestive heart failure (CHF) has undergone pro-
found transformations, from the use of medications that
immediately improve hemodynamic function and allevi-
ate symptoms, to pharmaceuticals that prolong survival by
blunting sympathetic nervous activity or interfering with
the renin—angiotensin—aldosterone pathway, both of which
participate in the progression of myocardial failure [1,2].
However, the evidence supporting the safety and efﬁcacy
of medications administered during phases of acute car-
diac decompensation is weaker [3,4]. Recent clinical trials
in patients presenting with cardiac decompensation sug-
gested that dobutamine [5] and milrinone [6] both increase
morbidity and mortality. Moreover, a retrospective analysis
of the Acute Decompensated HEart Failure National REg-
istry (ADHERE) found that the in-hospital mortality among
patients who had received intravenous dilators was lower
than that of patients treated with inotropes, after adjust-
ments for baseline clinical characteristics [7]. Therefore,
recent guidelines for the treatment of acute heart failure
recommend limiting the use of inotropes to patients pre-
senting with hypotension due to a low cardiac output [8,9].
Serum concentration of cardiac troponin T (cTnT) and
cardiac troponin I (cTnI) are markers of myocyte injury
[10,11] and independent prognostic markers in patients with
both chronic and acute heart failure [12—16]. Recently, we
observed a signiﬁcant increase in high sensitive troponin I
(hs-TnI), within 1 day of treatment with inotropes adminis-
tered for ADHF complicated by systolic hypotension [17,18].
However, it remains unclear whether treatment of ADHF
with vasodilators instead of inotropes mitigates the extent
of myocyte injury.
In this retrospective study, we used serial hs-TnI in
patients presenting with ADHF and a preserved systolic blood
pressure (SBP), to determine whether (1) treatment with
intravenous vasodilators limits the extent of myocyte injury,
and (2) the therapeutic response to intravenous natriuretic
peptide versus nitrates is different.
Methods
Study population
Non-consecutive patients, >18 years of age, admitted to the
intensive care unit of Hyogo Prefectural Amagasaki Hospi-
tal between June 2005 and March 2008 for management of
ADHF treated with vasodilators in absence of acute coronary
event, were included in this study by retrospective review
of their medical records. Patients were excluded from this
analysis if they (1) were treated with inotropes for systolic
hypotension, (2) had a history of myocardial infarction, per-
cutaneous angioplasty, or coronary bypass surgery within the
last 6 months, (3) had a hs-TnI concentration >1 ng/ml, or
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n-term decreases in hs-TnI and long-term adverse cardiac events.
ology. Published by Elsevier Ireland Ltd. All rights reserved.
1mm ST segment deviation on surface electrocardiogram
t initial presentation, or (4) suffered from renal failure
equiring dialysis. Blood samples were collected upon admis-
ion of the patient to the hospital for routine laboratory
creening tests. The results of stress scintigraphy or coro-
ary angiograms performed within the last 3 years were
sed to diagnose ischemic versus non-ischemic heart dis-
ase. After treatment, all patients seemed to be clinically
mproved. The study procedures were in accordance with
he institutional guidelines of the Hyogo Prefectural Ama-
asaki Hospital, and the study protocol conformed to the
thical guidelines of the 1975 Declaration of Helsinki.
easurement of biochemical markers
-type natriuretic peptide (BNP) and hs-TnI concentrations
ere measured by PATHFAST® assay (Mitsubishi Chemical
edience, Tokyo, Japan) at the time of initiation of treat-
ent with intravenous dilators (baseline), and at 5 h, and
and 7 days later. Patients with serum concentrations of
NP >2000 ng/ml were excluded from this analysis since it is
bove the upper limit of the assay.
tatistical analysis
ll results are presented as means± standard deviations.
ontinuous variables were compared by repeated mea-
ures analysis of variance, and dichotomous variables by
hi-square analysis. Patients with >20% decreases in con-
entrations of BNP and hs-TnI from baseline were classiﬁed
s biochemical responders [19]. The relationship between
iochemical response and clinical characteristics was exam-
ned by logistic regression analysis. Odds ratios (OR) and
5% conﬁdence intervals (CI) were calculated. Survivals
ree from rehospitalization for management of worsening
HF and deaths from CHF were analyzed by the actuar-
al Kaplan—Meier method, and compared by log-rank test.
p-value <0.05 was considered signiﬁcant. The JMP® for
indows statistical package, version 5.1 (SAS Institute Inc.,
ary, NC, USA) was used for all analyses.
esults
linical characteristics and management of the
tudy groups
he baseline clinical characteristics of the overall patientntravenous nitrates. The mean diastolic pressure and serum
NP concentrations at baseline were higher, and the total
ose of furosemide administered lower, in patients treated
ith carperitide than in patients treated with intravenous
itrates, although these differences did not reach statistical
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Table 1 Baseline characteristics of the study population and of each treatment group.
All patients (n = 36) Carperitide (n = 20) Nitrates (n = 16) p
Age, years 73± 10 72± 11 75± 9 0.33
Men 16 (44%) 10/20 (50%) 6/16 (38%) 0.51
Ischemic heart disease 8 (22%) 3/20 (15%) 5/16 (31%) 0.42
Atrial ﬁbrillation 18 (50%) 9/20 (45%) 9/16 (56%) 0.73
Creatinine, mg/dl 0.9± 0.3 0.9± 0.3 1.0± 0.4 0.08
Hemoglobin, g/dl 11.7± 2.3 12.1± 2.2 11.2± 3.2 0.31
Baseline
Blood pressure, mmHg
Systolic 153± 29 153± 29 153± 31 0.99
Diastolic 87± 19 92± 21 80± 14 0.06
Heart rate, bpm 91.7± 23.2 99.4± 22.5 82.1± 21.0 0.02
Oral medications
ACE or ARB 23 (67%) 12/20 (60%) 11/16 (69%) 0.73
Beta-adrenergic blocker 7 (20%) 5/20 (25%) 2/16 (12%) 0.42
Total furosemide dose in 7 days 66± 78 38± 34 90± 98 0.08
Baseline
BNP (pg/ml) 777± 465 904± 460 618± 434 0.07
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gHs-TnI (ng/ml) 0.069± 0.114
Values are means± standard deviation or numbers (%) of patients
ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptid
igniﬁcance. Continuous intravenous infusions of the recom-
inant -human atrial natriuretic peptide (ANP), carperitide
20—22] were administered for a mean of 6.4± 1.4 days to
0 patients, in a mean dose of 0.043± 0.018g/kg/min,
nd 16 patients were treated with intravenous nitrates
or a mean of 7.6± 3.4 days, of whom 13 received intra-
enous isosorbide dinitrate [23,24], in a mean dose of
.70± 0.25g/kg/min, and 3 received intravenous nitro-
lycerin in a mean dose of 0.55± 0.05g/kg/min.erial changes in mean BNP and hs-TnI
ompared with baseline, mean SBP and serum BNP concen-
rations were signiﬁcantly lower on day 1 and day 7 in both
B
l
M
d
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Table 2 Serial measurements of systolic blood pressure (SBP),
troponin I (hs-TnI) in the overall population and in each treatment
Baseline 5 h
Blood sampling time
SBP (mmHg)
All patients (n = 36) 153 ± 29 129
Carperitide (n = 20) 153 ± 29 128
Nitrates (n = 16) 153 ± 31 131
BNP (pg/ml)
All patients (n = 36) 777 ± 465 801
Carperitide (n = 20) 904 ± 460 941
Nitrates (n = 16) 618 ± 434 627
Hs-TnI (ng/ml)
All patients (n = 36) 0.069 ± 0.114 0.076
Carperitide (n = 20) 0.067 ± 0.091 0.074
Nitrates (n = 16) 0.073 ± 0.140 0.077
* p < 0.0001.0.067± 0.091 0.073± 0.140 0.86
responding group. ACE, angiotensin-converting enzyme inhibitor;
-TnI, high sensitive cardiac troponin I.
reatment groups (p < 0.0001). However, mean hs-TnI did not
hange signiﬁcantly in either study group (Table 2).
ercent changes in BNP and hs-TnI between
aseline and day 7
ince the clinical characteristics of the two treatment
roups were slightly different, the percent changes in SBP,
NP, and hs-TnI concentrations from baseline were calcu-
ated [19] and compared between the 2 groups (Fig. 1).
ean systolic blood pressure and BNP concentrations
ecreased signiﬁcantly from baseline in both treatment
roups (p < 0.0001). On day 1, the relative decreases in
B-type natriuretic peptide (BNP) and high sensitive cardiac
group.
Day 1 Day 7
± 20 118 ± 17 117 ± 14*
± 21 112 ± 13 117 ± 14*
± 20 124 ± 19 117 ± 15*
± 459 401 ± 256 327 ± 237*
± 434 375 ± 218 371 ± 247*
± 441 433 ± 302 272 ± 219*
± 0.121 0.062 ± 0.106 0.056 ± 0.089
± 0.10 0.060 ± 0.087 0.058 ± 0.084
± 0.146 0.064 ± 0.128 0.054 ± 0.098
High sensitive troponin I in decompensated heart failure
Figure 1 Percent changes in systolic blood pressure (SBP),
B-type natriuretic peptide (BNP) and high sensitive cardiac
troponin I (hs-TnI) concentrations from baseline. A signiﬁ-
cant decrease in SBP and BNP concentrations from baseline
was observed in both treatment groups (p < 0.0001). Compared
with patients treated with intravenous nitrates, a signiﬁcant
decrease in BNP (p < 0.001) and non-signiﬁcant decrease in SBP
were observed on day 1 in patients treated with carperitide.
However, these differences were no longer present on day 7.
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nNo signiﬁcant serial change in hs-TnI was observed in either
group. ANP, atrial natriuretic peptide.
mean systolic blood pressure and BNP concentration were
greater in patients treated with carperitide than in patients
treated with intravenous nitrates, though only the differ-
ence in BNP concentration reached statistical signiﬁcance
(p < 0.001). These differences were no longer observed on
day 7. The percent changes in serial serum hs-TnI concen-
tration between baseline and day 7 were insigniﬁcant and
similar in both treatment groups (Fig. 1).Biochemical responders and clinical characteristics
On day 1, >20% decreases in BNP [19] and hs-TnI from base-
line were observed in 27 patients (75%) and 12 patients
(33%), respectively. The baseline clinical characteristic
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c69
hown in Table 1 and the use of carperitide were entered
n a logistic regression analysis. By single variable analysis,
ge, hemoglobin, serum creatinine, and use of carperitide
orrelated with a >20% decrease in serum BNP concentra-
ion on day 1. When these 4 factors were entered into a
egression model, treatment with carperitide was the only
ndependent predictor of a BNP response on day 1 (Table 3).
se of carperitide remained an independent predictor after
djustment for gender and SBP (data not shown). By single
ariable analysis, hemoglobin was the only factor that cor-
elated with a >20% decrease in serum hs-TnI on day 1 (OR:
.42; 95% CI: 1.02—1.97; p = 0.032). However, after adjust-
ent for gender, the relationship was no longer signiﬁcant
data not shown).
On day 7, 30 of the 36 patients (83%) had a >20% decrease
n BNP and 20 of 36 patients (55%) had a >20% decreases in
s-TnI. On day 7, by measurements of serum hs-TnI, 11 of 20
atients treated with ANP (55%), and 9 of 16 patients treated
ith nitrates (56%), were biochemical responders (ns). By
ogistic regression analysis, no baseline clinical characteris-
ics had a signiﬁcant effect on the BNP or hs-TnI response
n day 7 (data not shown).
ong-term clinical outcomes
t a mean follow-up of 11.4 months, a single patient was
ost to follow up. Rehospitalizations for management of
DHF were needed in 6 patients treated with carperitide
nd 6 patients treated with nitrates. One patient treated
ith carperitide and three patients treated with nitrates
ied during rehospitalization. By Kaplan—Meier actuarial
nalysis, the rates of re-hospitalizations and death due
o worsening CHF were similar in both treatment groups
p = 0.51). Neither clinical characteristics listed in Table 1
or the use of carperitide were predictors of adverse car-
iac events by Cox proportional hazards analysis (data not
hown).
iscussion
erial measurements of cardiac troponin by
igh-sensitivity assay in ADHF
everal studies, including ours, have found cTnT or cTnI to
e independent prognostic markers in patients with chronic
HF or ADHF, and that the combined measurements of BNP
r N-terminal BNP and cTnT or cTnI identiﬁed the patients at
ighest risk [11—16]. However, few reports have examined
erial measurements of cardiac troponin, particularly in the
etting of ADHF [19], in part because high-sensitivity assays
f cTnT or cTnI were previously unavailable. While the
idely accepted deﬁnition of myocardial infarction speci-
es a <10% coefﬁcient of variation at the 99th percentile of a
ormal reference population [10], most currently available
ssays do not satisfy this criterion, and the serial changes
n cardiac troponin measured are ambiguous, particularly
t low serum concentrations. PATHFAST, used in this study,
ulﬁll the criteria of ‘‘high sensitive’’ and accurate at low
oncentration [25].
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Table 3 Factors correlated with a >20% decrease in B-type natriuretic peptide between baseline and day 1.
Logistic regression analysis
Single variable Multiple variable
Age, years 0.88 (0.79—0.98) p = 0.0256
Hemoglobin (g/dl) 1.49 (1.04—2.14) p = 0.0274
Creatinine (mg/dl) 0.040 (0.002—0.761) p = 0.0321
p = 0.
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levated hs-TnI in ADHF
lthough the pathophysiology of the rises in cTnT or cTnI
emains uncertain both in chronic CHF and in ADHF, (a)
ctivation of the renin—angiotensin—aldosterone, cytokine,
nd sympathetic nerve systems, (b) increased ventricular
all stress, and (c) relative ischemia, are putative causes
f myocyte injury in CHF, which have been correlated with
levated cTnT or cTnI [14,26]. In the setting of ADHF, these
dverse factors might be ampliﬁed [27,28] promoting fur-
her myocyte injury [3,18]. Therapeutic strategies to lower
TnT or cTnI might improve the prognosis of patients with
DHF. Recently, we reported that increased hs-TnI on day
is an adverse prognostic factor, and is associated with
ow SBP and the infusion of inotropic agents during treat-
ent of ADHF [17]. This observation supports the hypothesis
hat inotropic agents cause myocyte injury and worsen the
rognosis [3,18]. However, we are not aware of studies of
erial hs-TnI in patients with ADHF treated with intravenous
asodilators.
erial measurements of hs-TnI and vasodilators
he randomized, double blind, placebo-controlled trial,
asodilation in the Management of Acute Congestive Heart
ailure (VMAC), which compared nesiritide, a recombinant
uman BNP, with nitroglycerin in addition to standard ther-
py in patients with ADHF [29], found a signiﬁcantly greater
ecrease in pulmonary capillary wedge pressure associated
ith nesiritide. However, the 6-month mortality was simi-
ar in both treatment groups. Furthermore, a retrospective
nalysis of the ADHERE trial revealed that the risk of in-
ospital mortality among patients treated with nesiritide
ersus nitroglycerin was similar [7]. Therefore, to date,
reatment with a natriuretic peptide has not been found
o confer greater myocyte protection or to lower long-term
ortality, compared with nitroglycerin.
Nesiritide is not commercially available in Japan, while
he recombinant -human ANP, carperitide [20—22], has
een approved for the treatment of ADHF in presence of a
reserved SBP since 1995. In this study, BNP was signiﬁcantly
ower on day 1 among patients treated with carperitide com-
ared with patients treated with nitroglycerin, an effect
ndependent from the lowering of SBP. However, on day 7,
he difference in BNP between the 2 groups was no longer
igniﬁcant. This result may support the results of VMAC.
Although cases of renal insufﬁciency induced by nesiritide
ave been reported [30], we found no signiﬁcant difference
a
b
n
t
b0099 33.2 (1.4—757.4) p = 0.0279
n percent changes from baseline in creatinine on day 7,
etween patients treated with carperitide (1.16± 0.24) and
atients treated with nitrates (1.17± 0.17). However, this
tudy was not addressed to investigate the renal function,
ata of creatinine at 5 h and day 1 were not available. Fur-
her studies are necessary to investigate the renal effects
f the vasodilators in patients with ADHF.
Our previous study showed an increase of hs-TnI at day
was associated with the use of inotropes [17]. Therefore,
e excluded patients treated with inotropes from this anal-
sis. A decrease in hs-TnI was, nevertheless, not observed
n vasodilator treatment group during the ﬁrst 7 days, and
he long-term rates of adverse cardiac events were similar in
oth ANP and nitrates groups. Recently, Miller et al. reported
ersistently increased cTnT concentrations (not measured
y high-sensitivity assay) and the alleviation of symptoms
f ADHF after the infusion of nesiritide [19]. Though they
ound the results of their study ‘‘surprising’’, they seem to
upport our observations.
In conclusion, in ADHF patients with preserved SBP, the
dministration of intravenous vasodilators did not decrease
he release of hs-TnI over the ﬁrst 7 days of treatment. More-
ver, treatments with intravenous ANP and nitrates were
ssociated with similar short-term decreases in serum hs-
nI concentrations and long-term rates of adverse clinical
vents. A therapeutic strategy speciﬁcally designed to lower
he concentrations of hs-TnI needs to be developed.
tudy limitations
1) This retrospective, non-randomized, single-center study
ncluded a relatively small and non-consecutive series of
atients, and examined only the changes in BNP, hs-TnI,
nd SBP. Dyspnea, global clinical status, echocardiographic
xamination at admission, changes in body weight, urinary
utput, and hemodynamic measurements were not ana-
yzed. (2) Although, in all our previous studies, baseline BNP
nd troponin were predictors of adverse events in patients
ith chronic CHF or ADHF [12,13,15,26], baseline BNP and
s-TnI were not predictors in this analysis. This discrepancy
s probably due to the exclusion of patients with baseline
NP >2000 pg/ml, who are at highest risk, biasing the results
f this study. (3) In this study, the hs-TnI concentrations
fter day 7 and discharge were not available and a possi-
le delayed decrease in troponin concentrations [31] was
ot examined. (4) The factors inﬂuencing the concentra-
ions and biological variations in hs-TnI [32,33] have not
een elucidated and were not addressed in this study.
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